Phase 1 Study of DS-6051b in Japanese Subjects with Advanced Solid Malignant Tumors Harboring Either a ROS1 or NTRK Fusion Gene

DAIICHI SANKYO CO., LTD.0 个研究点目标入组 15 人开始时间: 2015年12月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Advanced solid malignant tumors that are refractory to standard therapy or for which no standard therapy is available.
•-An Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

•-Previously had or currently has any of the following diseases:
•Cardiac failure (NYHA Functional Classification >= Class III), myocardial infarction, cerebral infarction, unstable angina, arrhythmia requiring treatment, coronary/peripheral artery disease, pulmonary thrombosis, uncontrolled deep vein thrombosis, clinically severe thromboembolic event, or autoimmune disease requiring treatment.
•-Previously had or currently has clinically severe pulmonary disease (eg, interstitial pneumonia, pneumonitis, pulmonary fibrosis, radiation pneumonia).
•-Severe or uncontrolled concomitant disease.
•-Clinically active brain metastases or central nervous system tumor requiring steroid or anticonvulsant treatment.

发起方